10 funding opportunities are listed in this category
Cystic Fibrosis Foundation Pilot and Feasibility Awards and Research Grants
The CF Foundation offers competitive awards for research related to cystic fibrosis. Studies may be carried out at the subcellular, cellular, animal, or patient levels. Two of these funding mechanisms include Pilot and Feasibility Awards and Research Grants. Investigators who seek support from the Foundation under these funding mechanisms must submit a Letter of Intent (LOI) by May 1st. Pilot and Feasibility Awards and Research Grants are issued primarily for basic science research. Those proposals that include methodologies requiring sampling of materials from human subjects will only be considered under this mechanism if the sampling method constitutes minimal patient risk (e.g., venipuncture) and patient samples or data are anonymous. For applications where more invasive procedures are proposed or where patient samples or data will not be anonymous, please submit a Letter of Intent for a Clinical Research Award.
Application SubmissionsLOIs and applications must be submitted electronically at Proposal Central by 5:00pm (EDT) on the deadlines noted below. Letter of Intent for Basic Research A brief description of the proposed research must be submitted in advance for Pilot and Feasibility Award and for Research Grant applications. Please review the Guidelines for complete submission information, as well as a list of research areas currently of interest to the CF Foundation. Pilot and Feasibility Awards Letter of Intent Deadline: May 1st Application Deadline: First Wednesday of October to Proposal Central by 5:00 pm (EDT). These grants are for developing and testing new hypotheses and/or new methods, and to support promising new investigators as they establish themselves in research areas relevant to CF. Proposed work must be hypothesis driven and must reflect innovative approaches to critical questions in CF research. The award is not meant to support continuation of programs begun under other granting mechanisms. Funding priority will be placed on those projects proposing to better understand the mechanisms behind disease pathophysiology and to develop strategies to prevent or treat it. Up to $40,000 per year (plus 8% indirects) for two years may be requested.
Research Grants Letter of Intent Deadline: May 1st Application Deadline: First Wednesday of October to Proposal Central by 5:00 pm (EDT). This grant mechanism is intended to encourage the development of new information that contributes to the understanding of the basic etiology and pathogenesis of CF. Funding priority will be placed on those projects proposing to better understand the mechanisms behind disease pathophysiology and to develop strategies to prevent or treat it. All proposals must be hypothesis driven, and sufficient preliminary data must be provided to justify CFF support. Information derived from such studies will hopefully lead to submission to other funding agencies, such as the National Institutes of Health (NIH). Support is available for $90,000 per year (plus 8% indirects) for a period of two years, at which time a grant may be competitively renewed for an additional year of funding. Please review the Policies and Guidelines for complete submission information.
For More Information Investigators interested in any of the above-mentioned funding programs may contact the Grants and Contracts Office for further information and/or to discuss the potential relevance of their research to the mission of the CF Foundation and to the objectives of these programs. Please direct inquiries to: Cystic Fibrosis Foundation Grants and Contracts Office 6931 Arlington Road Bethesda, MD 20814 (800) FIGHT CF (301) 951-4422 grants@cff.org
CUREPSP Society for Progressive Supranuclear Palsy Investigator-Initiated Research Projects
Grant submission deadline is April 1, 2010 Two, CBD-related grants are available for up to $75,000 for a period of one to two years
VISION Cure and prevent PSP and CBD
MISSION STATEMENT Increase awareness of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), fund research toward a cure and prevention, educate health professionals, and provide support, information and hope for persons and families with PSP and CBD.
The Society for Progressive Supranuclear Palsy (CurePSP) Research Program supports and promotes research that can advance the understanding and treatment of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD).
INVESTIGATOR-INITIATED RESEARCH CurePSP promotes research that helps generate an integrated picture of PSP and CBD at the molecular, cellular, and clinical levels.
CurePSP is particularly interested in research that will help us: 1. Understand the role of the tau gene and other genes in PSP and CBD. 2. Understand the role of tau protein processing in PSP and CBD. 3. Understand cellular energy metabolism and oxidative stress perturbations in PSP and CBD. 4. Understand environmental factors that influence the development or course of PSP and CBD. 5. Understand the series of changes brain cells pass through in PSP and CBD as they progress from healthy neurons to dysfunctional neurons. 6. Characterize the natural history of PSP and CBD in order to develop outcome measures for clinical trials. 7. Develop animal models of PSP and CBD. 8. Develop tools and disease markers for early diagnosis of PSP and CBD and for assessment of treatment. 9. Develop treatments that improve the symptoms of persons with PSP and CBD. 10. Develop interventions to arrest the progression of PSP and CBD and restore lost function.
CurePSP Executive Plaza III 11350 McCormick Road, Suite 906 Hunt Valley, MD 21031 Phone: 800-457-4777 E-mail: info@curepsp.org Website: www.curepsp.org
Request for Applications for the American Cancer Society MEN2 Thyroid Cancer Consortium
The American Cancer Society announces this revised Request for Applications for the American Cancer Society MEN2 Thyroid Cancer Consortium. Up to seven (7) Research Scholar and/or Mentored Research Scholar grants and up to five (5) Postdoctoral Fellow grants will be awarded. The Consortium will be led by a single renowned senior scientist who will be awarded the American Cancer Society MEN2 Thyroid Cancer Professorship and act as leader for the overall program (details at links below). Appropriate areas of investigation include, but are not limited to: understanding consequences of RET mutations, molecular events underlying the development of MEN2-related tumors, improved animal models of MEN2, new screening and monitoring tools, new imaging approaches, and new pharmacologic and other strategies to blunt the effects of mutations in RET and other genes associated with medullary thyroid cancer.Individuals applying for a Research Scholar Grant must have an independent research or faculty position and can be at any stage of their career. These grants will be awarded for up to $200,000 a year, direct costs, for 5 years. Mentored Research Scholar Grants will be awarded to junior faculty members with a doctoral degree in a clinical or cancer control research discipline (e.g., M.D., and/or Ph.D.) that are within the first four years of a full time faculty appointment or equivalent, and have no more than 4 years of postdoctoral research experience immediately prior to their faculty appointment. The successful applicant is expected to transition into a career as an independent investigator. Awards are for up to five years and for up to $135,000 per year direct costs.Applicants for Postdoctoral Fellowships must have obtained their doctoral degree prior to activation of the fellowship. Awards are for three years with progressive stipends of $44,000, $46,000, and $48,000 per year, plus a $4,000 per year fellowship allowance. Individuals who have held a PhD or MD for more than 4 years at the time of application are not eligible.Deadline: Complete applications are due by April 1, 2010. Funding will begin January 1, 2011. For information regarding funding policies or to obtain an application, go to https://proposalcentral.altum.com or refer to the ACS website at www.cancer.org/research: select Funding Opportunities followed by Index of Grants, scroll down to Special Initiatives and select the appropriate RFA for MEN2 Thyroid Cancer.Charles Saxe, PhDScientific Program Director(404) 929-6919Charles.Saxe@cancer.org
New Research Grants for Novel Approaches to Lupus
Grant Application Deadline: May 28, 2010The Lupus Research Institute (LRI) – founded to support highly promising, idea-driven, novel approaches to discover the cause, improve treatment, and cure lupus – invites applications for financial support starting December 2010 for Novel Research Projects relevant to Systemic Lupus Erythematosus.Research applications will be judged principally on novelty of the hypotheses, scientific quality, strength of approach, relevance to lupus, and likelihood of success. Creativity will be valued. Rationale for the hypotheses proposed rather than amount of preliminary data will be emphasized.Continuations of long-term research projects are not appropriatefor this submission.Projects on aspects of the disease that have been less extensively studied and applications from investigators in diverse disciplines, including those who may not have previously worked in lupus, are encouraged. Investigations should be relevant to basic, translational, or clinical research on lupus.While the Institute encourages projects based on novel explorations of human lupus biology—innovative studies that use human material to address the physiological, cellular, molecular and/or genetic basis of human lupus—projects solely based on cellular, molecular, and/or animal models are also encouraged. Both established and new investigators may apply. Applicants should hold advanced degrees and be affiliated with institutions of higher learning in the United States. Grant application research plans are limited to six pages. Annual funding of up to $100,000 per year, for a term of up to three years, will be awarded for approved projects.For additional information please visit the LRI website – www.lupusresearchinstitute.org – or contact Laura Hack, Grants Administrator lhack@lupusny.org or 212.685.4118.
Lupus Research Institute330 Seventh Avenue, Suite 1701New York, NY 10001T: 212.812.9881 F: 212.545.1843Lupus@LupusNY.org
Targeted RFP – Biomedical Research: Establishment of a Research Consortium to Explore the Barriers to and Potential for Eradication of HIV Infection
Application Deadline: March 25, 2010 Available Support amfAR, The Foundation for AIDS Research, is pleased to announce plans to establish and support a consortium—consisting of several collaborations—of biomedical researchers to explore the barriers to and potential for eradicating HIV infection. Funding will be available for: Collaborations—Each collaboration is funded for a total of up to $300,000 for direct costs plus up to 20 percent for indirect costs. The performance period for collaborations funded under this RFP will be for one year starting May 1, 2010, and may be renewable for subsequent years. Each collaboration must consist of at least two interrelated research projects and involve at least two independent, faculty-level researchers. Background and Areas of Interest amfAR's research program is driven by the Foundation's mission to end the global AIDS epidemic through innovative research. amfAR plays a uniquely important role in AIDS research, identifying critical gaps in our knowledge of HIV and AIDS and supporting groundbreaking studies that often lack the preliminary data required by more traditional funders. The Foundation's research program focuses on efforts to prevent HIV infection among vulnerable populations and to improve treatment, with the ultimate goal of eradicating the virus in people living with HIV infection. This RFP solicits proposals for collaborations to explore the obstacles to and strategies for eradicating HIV infection. Highly active antiretroviral therapy (HAART) has significantly improved the health of individuals infected with HIV-1. However, if therapy is interrupted, there is a rapid resumption of viral replication. Understanding the mechanisms by which the virus is able to persist in the face of therapy is necessary in order to identify strategies that may interrupt viral persistence and ultimately lead to viral eradication. amfAR wishes to establish a consortium consisting of several collaborations. The purpose of the consortium is to explore barriers to and the potential for the eradication of HIV infection as a condition requiring medical treatment, i.e., a sterilizing or functional cure. amfAR would like to fund one collaboration in each of the following three areas. Some, but not all, potential topics of interest within each of the three collaboration areas are listed: Sterilizing cure: i.e., eliminating HIV from the body of an infected person Gene therapy techniques/vectors "Shock and kill” strategies Methods to identify and specifically target infected cells Replication and/or exploration of factors contributing to the Berlin patient outcome Functional cure: i.e., achieving a state of persistent HIV infection without the need for medical treatment What can be learned from specific populations of interest such as elite controllers, long-term non-progressors, and patients who initiate therapy during acute infection? How can this information be applied to devising a functional cure? What are the immune or other implications of persistent infection, even in the absence of disease? Characterizing viral reservoirs: Which cells under which conditions contribute which roles to the reservoir(s)? Mechanisms for reservoir maintenance Assays to measure perturbation of reservoir Latency and the extent to which it exists in different cell types Nature and origin of blips Animal models
Definitions and exclusions Each collaboration must consist of at least two interrelated research projects and involve at least two independent, faculty-level researchers. All principal and collaborating investigators must be doctoral level. Each collaboration must have access to and describe how they would use patients or clinical samples as part of their research plan. Any collaboration participant, i.e., principal or collaborating investigator, key personnel (including postdoctoral researchers and their mentors), and consultants, may be part of only one application. Special notes Please note that this RFP is differs from recent ones in the following ways: Grants will be awarded to support collaborations, not individual researchers. The direct cost maximum is $300,000. Funding may be renewable. Pre-submission forms and letters of intent are not required. Eligibility and Qualifications Collaborative research grants are awarded to nonprofit institutions worldwide to support investigator-led projects approved by the Foundation. They are not awarded to for-profit entities or to individuals. With the exception of colleges or universities, governmental units or agencies are not eligible to receive funding through grants made under this RFP. The recipient organization will be legally and financially responsible for the use of grant funds. Principal and collaborating investigators must be doctoral-level researchers and hold a faculty-level (or equivalent) position. The principal investigator must be affiliated with the applicant organization. The principal investigator will be expected to actively lead one of the component projects; actively participate in the development, implementation, and analysis of the project as whole; and be responsible for coordinating the preparation and submission of required progress reports. Collaborating investigators may be affiliated with any research organization that is not a governmental unit or agency. Collaborating investigators are expected to actively lead a component project and play an active role in the development, implementation, and analysis of the project as a whole. Forms, Instructions, and Deadlines The preferred method for obtaining application forms is to e-mail amfAR at grants@amfAR.org. We will send a complete set of forms and instructions.
Completed applications are to be e-mailed to grantapps@amfar.org no later than March 25, 5:00 p.m. EDT. Please make sure the body of the e-mail includes the principal investigator’s name and contact information. Important Notice Pre-submission notice and letters of intent are NOT required under this RFP. Applications that are received late, are incomplete, or exceed word limitations will not be accepted for review. Fax submissions are not accepted. The Research Plan consists of separate research plans of no more than 2,500 words for each of the component projects covering background and rationale, preliminary studies, specific aims, experimental design, procedures, and data analysis to be used. There are no forms for the research plan; formatting and submission requirements are detailed in the application instructions. Send one hard copy of the Collaboration Information Form (bearing original signatures) to: amfAR Grants 120 Wall Street, 13th Floor New York, NY 10005-3908, USA If you are not able to download the forms or have questions about the application requirements, please e-mail grants@amfar.org or telephone 212-806-1752. Submission of an application is not a guarantee of funding. The review and approval process is highly competitive.
American College of Phlebology Junior Faculty Investigator Grant
The ACP Junior Faculty Investigator Grant Program will assist new investigators with a career interest in phlebology research in initiating a basic, pre-clinical, or pilot clinical research project of importance to the field of Phlebology. This Program is expected to: 1) generate pilot data that enhances the recipient's ability to independently obtain major grant funding for future Phlebology research; and 2) enhance the recipient's ability to independently design, conduct, and report Phlebology research. The Program's long-term goal is to promote the development of a future generation of phlebology research leaders.
EligibilityJunior faculty investigators with an MD, DO, PhD, or equivalent degree from an accredited educational institution are eligible. Non-ACP members will be considered, but ACP members will be given preference. Applicants must not have been recipients of major grant support (exceeding $50,000). Established investigators at the Associate Professor or Full Professor level are not eligible. To ensure balance, independence, objectivity, and ethical rigor in its funded research activities, all research applicants are required to complete a Financial Disclosure Statement. A full disclosure of any professional business dealings and/or interests in for-profit commercial entities (medical device or pharmaceutical companies, as well as private practices), is required by all applicants. This disclosure will not preclude eligibility of an applicant, rather it will be weighed in the grant approval process.
AwardThis grant provides $70,000 for one year. Funds may be used for Investigator salary support, salaries of research assistants working on the project, supplies, service function charges, travel expenses for 1-2 related conferences, and completion of a research education program. Consulting expenses, institutional indirect costs, and office expenses will not be funded. Investigators must spend at least 40% of their time on the project.We will begin accepting applications in the fall of 2009. Applications are DUE on April 1, 2010.
American College of Phlebology101 Callan Avenue, Suite 210San Leandro, California94577 USA Phone 510.346.6800Fax 510.346.6808
American College of Phlebology Research Trainee Grant
The ACP Research Trainee Grant Program is designed to provide young investigators not yet professionally established in the phlebological sciences with an opportunity to gain insight into scientific investigation in the field of phlebology. The Program's long-term goal is to promote the development of a future generation of phlebology research leaders.
EligibilityTrainees in graduate-level medical or research programs (e.g. medical students, residents, fellows or post-doctoral students) are eligible. Trainees must be supervised by a designated research mentor at their institution who has an MD, DO, PhD, or equivalent degree. Applicants must not have previously received major grant funding (exceeding $50,000). To ensure balance, independence, objectivity, and ethical rigor in its funded research activities, all research applicants are required to complete a Financial Disclosure Statement. A full disclosure of any professional business dealings and/or interests in for-profit commercial entities (medical device or pharmaceutical companies, as well as private practices), is required by all applicants. This disclosure will not preclude eligibility of an applicant, rather it will be weighed in the grant approval process.
AwardThis grant provides $45,000 for one year. Funds may be used for Investigator salary support, salary for research assistants, supplies, service function charges, and travel expenses for attendance at 1-2 related conferences. Funds may also be used to fulfill the research education requirement associated with this program. Consulting expenses, institutional indirect costs, office expenses, and salary for research mentors will not be funded. Investigators must spend at least 50% of their time on the proposed project.We will begin accepting applications in the fall of 2009. Applications are DUE on April 1, 2010.
American College of Phlebology Research In-Practice Grant
The ACP Research-In-Practice Grant is designed to assist clinical phlebologists who are not established as independent researchers in initiating a clinical research project of importance to the field of phlebology. The long-term intent of this program is to foster the research education and development of clinical phlebologists who are capable of active participation in and/or leadership of clinical trials of phlebological therapies.
EligibilityInvestigators with an MD, DO, PhD, or equivalent degree are eligible. Non-ACP members will be considered, but ACP members will be given preference. Applicants must not have been recognized as independent investigators or recipients of major grant support (exceeding $50,000). To ensure balance, independence, objectivity, and ethical rigor in its funded research activities, all research applicants are required to complete a Financial Disclosure Statement. A full disclosure of any professional business dealings and/or interests in for-profit commercial entities (medical device or pharmaceutical companies, as well as private practices) is required by all applicants. This disclosure will not preclude eligibility of an applicant, rather it will be weighed in the grant approval process.
AwardThis grant provides $24,000 for one year. Funds may be used for salaries for research assistants working on the project, supplies, service function charges, travel expenses for attendance at 1-2 related conferences, and completion of a research education program. Consulting expenses, institutional indirect costs, and office expenses will not be funded.We will begin accepting applications in the fall of 2009. Applications are DUE on April 1, 2010.
Michael E. DeBakey Journalism Awards
The Michael E. DeBakey Journalism Awards, named after FBR’s late chairman Dr. Michael E. DeBakey, honor professional journalists whose reporting has enhanced public understanding of how the humane and responsible use of animal models leads to medical and scientific discoveries. FBR also welcomes entries that demonstrate how animal rights extremism poses a serious threat to researchers and the future of science. Awards are presented for outstanding investigative or interpretive reporting published, broadcast or posted online between April 1, 2009 and March 31, 2010. Award winners will receive a Michael E. DeBakey Award and a trip to Washington, D.C., to attend the awards ceremony at the Mayflower Hotel. Entries may be submitted in the following categories: * Print (large market) * Print (small market) * Print series * Television * Radio * InternetEntries must be accompanied by the following: a cover letter from journalist or employer, a biography of journalist, letter of consent from journalist and letter(s) of support (optional). Submit by April 30, 2010 to: info@fbresearch.org, Subject: The Micheal E. DeBakey Journalism Awards or Foundation for Biomedical Research818 Connecticut Avenue NW, Suite 900Washington DC 20006Attention: The Michael E. DeBakey Journalism Awards
1
